New startup ideas · Health and bio · Healthcare and bio
startup idea
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
- AI agent as a service
- Enterprise
- $10-100B market
- Network effects, winner takes most
- Global from day one
5/5
venture judge
16
similar startups, last 2 years (96 all-time)
97%
of 4 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$3,700 · 4 weeks · 25 prospects
For $3,700 in 4 weeks, prove that seed-stage biotech scientists will prepay an unknown broker $1,000 to route a protein expression and binding assay, and that two contract labs return comparable results on the same protocol.
Riskiest assumption · A scientist at a seed-stage biotech will sign and prepay a broker they have never worked with to route a protein expression and binding assay, instead of emailing a CRO they already know, when offered a 48-hour quote and a three-week guaranteed turnaround.
1Focus group: who and where
The founder or lead scientist at a seed-stage biotech with no in-house wet lab, who has a construct sitting in a freezer or a sequence in a file and is currently emailing three CROs for expression and binding quotes that take two weeks to arrive.
where to find 25 · The Bits in Bio Slack community, where biotech-adjacent founders and scientists discuss outsourcing daily; the public resident-company directories of LabCentral and BioLabs incubators, which list exactly the seed-stage companies that rent benches but outsource assay work; Nucleate chapter events in Boston and the Bay Area, where pre-wet-lab founding teams congregate.
2Sell first, build later
A fully brokered assay run before any software exists: quote within 48 hours, routing to a vetted contract lab, sample tracking, and delivery of structured results plus raw instrument files three weeks after quote approval.
the ask · The contract lab's price plus a flat 15 percent routing fee, with a $1,000 deposit credited against the total
a real yes · A real yes is a signed one-page SOW and a $1,000 deposit paid by card or wire. 'Send me the quote' emails, enthusiastic calls, and offers to try it free are not yeses.
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Fifteen outsourcing discovery calls
$100 · 10 days
DM 40 founders from Bits in Bio and the LabCentral and BioLabs directories to book 15 twenty-minute calls. Ask what expression and binding work they outsourced in the past 6 months, what it cost, how long quoting took, and whether they have a live assay that needs a lab in the next 60 days.
keep going if · 9 of 15 outsourced expression or binding work in the past 6 months, and 6 of 15 have a live assay need within 60 days
2. Quote-and-deposit sell
$200 · 14 days
For every call that surfaces a live need, deliver a real quote within 48 hours by pricing the assay with two contract labs sourced through Science Exchange listings, marked up a flat 15 percent, packaged as a one-page SOW: routed run, structured results plus raw instrument files, three-week turnaround, $1,000 deposit to start. The founder does all routing by hand, which is the honest version of the agent.
keep going if · 3 of 8 quoted prospects sign the SOW and pay the $1,000 deposit
3. Two-lab comparability run
$3,400 · 21 days
Send the identical His-tagged protein expression and purification protocol, same sequence and same acceptance criteria, to two different contract labs and compare yield and purity. This is the cheapest possible test of the stated risk that cross-lab variance makes the results graph noise, run in parallel with the selling.
keep going if · Yield within 2x and purity within 10 percentage points between the two labs on the same protocol
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$1,000
per prospect, refundable
how · A $1,000 deposit invoiced against the signed SOW for the first routed assay, roughly 1-3 percent of what a seed biotech spends yearly on outsourced preclinical work. The founder or lead scientist signs the SOW and pays by card or ACH; the deposit is credited in full against the final assay invoice, so it costs the buyer nothing extra and costs a tire-kicker everything. set up: Stripe Invoicing ↗
what it reserves · A guaranteed lab slot with the run starting within 10 business days of quote approval and the three-week delivery date in writing
refund · Refunded in full if the assay is not placed with a qualified lab within 10 business days of quote approval.
target · 3 paid deposits from 8 quotes within 28 days
Go: build it if
3+ paid $1,000 deposits from 8 quotes, 6+ of 15 calls surfacing a live 60-day assay need, and the two-lab run landing within 2x yield and 10 purity points: buyers prepay strangers and the results graph can be real, so build the routing layer.
Kill: stop if
Fewer than 2 deposits from 8 quotes, or the two labs diverge by more than 2x yield or 15 purity points on an identical standard protocol: either scientists will not prepay an unknown broker or the network's data asset is noise, and either one ends the thesis.
5 Scripts to run itoutreach message, landing copy, deposit terms · click to open
outreach message
You are running a biotech without a wet lab, which usually means every expression or binding run starts with a week of emailing CROs for quotes. I quote your assay within 48 hours, route it to a vetted contract lab, and hand back structured results plus the raw instrument files three weeks later, at the lab's price plus a flat 15 percent. If you have a construct waiting on a lab right now, give me 20 minutes this week and you will have a real quote by Friday.
landing page
One assay, one quote, results in three weeks Lab price plus a flat 15 percent; a $1,000 deposit starts your run within 48 hours of quote approval Request your 48-hour quote
deposit terms
A $1,000 deposit books your run and is credited in full against your quoted assay price. If we cannot place your assay with a qualified lab within 10 business days of quote approval, it is refunded in full. The balance is invoiced only on delivery of your structured results and raw instrument files.
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
76
Idea Score, 0-100 · raw 47.5 x 1.61
Crowded
competition: more crowded than 79% of ideas · headwind x0.60
+4.5
government priorities, secondary (104 matching grants)
Trend
66
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)70
- Rounds announced 2025+ in the sector69
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
68
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain75
100x potential
80
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge100
- Market size axis67
- Moat axis100
- Neighbours still alive62
- Technologist judge50
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were design, order, preclinical, experiments, global, biotech, pharma, scientist.
The idea in full
- What
- Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files. It owns no labs; it owns the protocol translation layer and the results graph. Any scientist can start with a credit card and one assay, and teams expand from there.
- Why now
- The S26 and W26 cohorts show the demand and the gap at once: Omanta is building "a research lab for one", 10x Science and AbInitio Bio are building AI layers for protein characterization and drug manufacturing, and Harbor (yc X26) is an AI-native CRO for clinical trials, leaving preclinical experiment routing across existing labs unclaimed.
- Wedge: first customer and entry point
- Seed-stage biotechs with no in-house wet lab: start with one assay class, protein expression and binding, where protocols are standard enough to route reliably across five labs.
- Path to 100x
- Global preclinical contract research is a $10-100B annual spend routed today by relationships and email. Denser lab supply means faster and cheaper turnaround, which pulls more sponsors, which pulls more labs, and every completed run adds a protocol-to-outcome pair that no competitor can buy, so the first network to reach density compounds away from the second.
- Ceiling
- Large pharma keeps routing through preferred-vendor master agreements and never lets an agent choose the lab, leaving Labmesh with only small biotechs and a market an order of magnitude smaller.
- Closest real companies, as the generator saw them
- Harbor (yc X26) is an AI-native CRO for clinical trial operations, which is regulated and asset-owning; Labmesh stays preclinical and asset-light. 10x Science and AbInitio Bio build intelligence layers for a single stage; Labmesh sits across labs and stages and keeps the outcome data.
- Main risk
- Contract labs execute the same protocol differently enough that results are not comparable, and the results graph becomes noise instead of a training set.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
5/5
Asset-light routing across a $10-100B preclinical spend, self-serve entry, and every run adds protocol-to-outcome data a rival cannot buy.
Bootstrapper
4/5
Asset-light routing across existing contract labs, credit-card start with one assay, taking a cut of spend biotechs already send by email.
Operator
4/5
Preclinical routing by relationships and email is a $10-100B spend already flowing, and one assay with a credit card fits how scientists buy.
Technologist
3/5
Protocol translation across five contract labs is real, but owning no instruments means execution variance may make the results graph unusable.
Risk
4/5
Owns no labs, unregulated preclinical work, credit-card self-serve across five interchangeable contract labs, so no single supplier or platform can end it.
trends
2/5
Marketplace routing of contract assays predates this cycle by a decade; the cohort-gap argument is absence of rivals, not a shift enabling the product.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (design, order, preclinical, experiments, global, biotech, pharma, scientist): 96 all-time, 16 from the last two years. Same matching as Idea Check.
Making hard molecules for Pharma and Biotech
AI Inference Platform for Drug Discovery
Developer of a research intelligence platform designed to accelerate biomedical discoveries. The company's platform uses machine learning and artificial intelligence to translate both closed and open-access data into recommendations for specific experiments regarding antibody extraction, enabling researchers and scientists to run successful experiments in less time without wasting resources.
The only R&D data cloud for life sciences
The robotic cloud laboratory for the life sciences.
Provider of an application programming interface designed to offer voice communication services. The company's application programming interface offers globally available cloud API that developers can interact with to build intelligent and complex communications systems, enabling customers to build sales automation systems, order inquiry lines, use CRM applications, call routing applications, phone trees, appointment reminders as well as customize voicemail applications.
SFOX is a cryptocurrency trading platform designed to create a global network of exchanges to facilitate real time trading of any currency.
Automata is a global biotech company providing robotic automation solutions to the life sciences industry.
Maximum information per experiment, minimum experiments per conclusion
Quote.trade is a cryptocurrency trading platform that offers dark pool exchange services for digital assets.
Affordable, intelligent humanoid robots built to deploy at scale
Curing cancer. Starting with dogs.
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1595
startup-relevant grants in Healthcare and bio
$854M
awarded in the sector, tracked
118
opportunities open now in the sector
NIH / NCATS · SBIR phase II · $1M · posted 2026-09-15
- A novel siRNA therapeutic to prevent scarring and bleb failure after trabeculectomyawardhigh relevance
NIH / NEI · SBIR phase II · $1M · posted 2025-09-15
- Rapid and Highly Multiplexed Pathogen Detection for Sepsis Patients with Compressed Sensing and Digital PCRawardhigh relevance
NIH / NCHHSTP · SBIR phase I · $296K · posted 2026-09-30
- Preclinical development of novel dual EZH2-BRD4 inhibitor for EZH2-mutant lymphomaawardhigh relevance
NIH / NCI · SBIR phase I · $385K · posted 2026-09-22
- Scale-up GMP Manufacturing of Extended-Release PNA5 for Treating Cognitive Impairment in Patients at-risk for Alzheimer's Disease-Related Dementias and Vascular Dementiaawardhigh relevance
NIH / NIA · SBIR phase I · $500K · posted 2026-09-22
- A massively parallel cell-based platform for the rational discovery of molecular gluesawardhigh relevance
NIH / NIGMS · SBIR phase II · $349K · posted 2026-09-19
- Low-cost technology for image-guided photodynamic treatment of oral lesions in resource-limited settingsawardhigh relevance
NIH / NCI · STTR phase I · $315K · posted 2026-09-18
- An allogeneic and gut specific Engineered T regulatory cell therapy for the treatment of Inflammatory Bowel Diseaseawardhigh relevance
NIH / NIDDK · SBIR phase II · $1M · posted 2026-09-17
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 135 → 121 → 224 → 173 → 127 new companies 2022 → 2026 · 91% aliveYC F26 live: 2 in this cluster, 2% of the batch (was 6% in S26)Since February, of 442 YC companies here: 6 acquired, 6 shut down, 45 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- AI agent as a service
- Path to 100x
- Network effects, winner takes most
- Market size
- $10-100B market
- Capital intensity
- Capital-medium (ops, field teams)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Self-serve
- Moat
- Data moat
- Geography
- Global from day one
- Regulation
- Unregulated
- Vibe
- Hot space
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Health and bio · Healthcare and bio
Claimsmith
The agent platform where healthcare's back office gets rebuilt by everyone but us.
Claimsmith is a no-code platform where hospitals, billing companies, and health IT vendors build and run AI agents for administrative work: eligibility checks, prior authorization, claims appeals, and records chasing.
Fictional company written 2026-08-23 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.